Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
This randomized trial assesses the effect of adjuvant therapy with camrelizumab after chemoradiotherapy on 3-year event-free survival among patients with locoregionally advanced nasopharyngeal carcinoma.
This randomized trial assesses the effect of adjuvant therapy with camrelizumab after chemoradiotherapy on 3-year event-free survival among patients with locoregionally advanced nasopharyngeal carcinoma.
